Christine K. Ward
VP, Head of Translational Medicine for Therapeutics at Moderna
Summary
Work
Education
Writing
Messenger RNA-Based Therapeutics and Vaccines: What's beyond COVID-19?
January 1, 2023Review article surveying the landscape, trends, patents, and clinical development of mRNA therapeutics and vaccines.
Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study
January 1, 2016Phase 2a randomized, double-blind, placebo-controlled study assessing benralizumab in patients with eosinophilic COPD.
Compositions and methods of using cells derived from umbilical cord tissue to stimulate and support lung tissue angiogenesis (patent application 20100158877)
June 1, 2010Patent application (inventor listing includes Christine K. Ward) describing compositions and methods using umbilical cord-derived cells to support lung tissue angiogenesis and regeneration.
Bronchial mucosal IFN-α/β and pattern recognition receptor expression in patients with experimental rhinovirus-induced asthma exacerbations
Study examining bronchial epithelial type I interferon and pattern recognition receptor expression at baseline and after experimental rhinovirus infection in asthmatic patients and controls.
Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study
Phase 2b dose-ranging randomized study of benralizumab for uncontrolled eosinophilic asthma.